ASBP ASPIRE BIOPHARMA HLDGS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ASPIRE BIOPHARMA HLDGS INC reported revenue of $63.1K, net income of −$1.27M and diluted EPS of −$1.22; for the fiscal year ended December 2025 revenue was $6.20K.
ASBP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $6.20K, gross profit −$116, operating income −$19.4M, net income −$24.5M (margin -394725.1%), EPS −$16.38
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$1.21M, net income −$1.31M (margin n/a), EPS −$1.90
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income n/a, net income $4.46M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income $3.34M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income n/a, net income −$25.5K (margin n/a), EPS n/a
ASBP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $63.1K, net income −$1.27M, EPS −$1.22
- Quarter ended Mar 31, 2026: revenue $28.4K, net income −$3.22M, EPS −$20.57
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.71M, EPS $536.73
- Quarter ended Sep 30, 2025: revenue $1.94K, net income −$1.85M, EPS −$0.04
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.98M, EPS −$48.19
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.9M, EPS −$504.88
- Quarter ended Dec 31, 2024: revenue n/a, net income −$766K, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$216K, EPS −$0.01
- Quarter ended Jun 30, 2024: revenue n/a, net income −$96.9K, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$231K, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$151K, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$69.3K, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income $1.81M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income $2.87M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $2.23M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income $1.08M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income $121K, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$87.8K, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$755, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$15.3K, EPS n/a
ASBP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.92M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$265K, share buybacks $13.8M
- Fiscal year ended Dec 2023: operating cash flow −$653K, share buybacks $285M
- Fiscal year ended Dec 2022: operating cash flow −$1.41M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$239K, share buybacks n/a
ASBP balance sheet
- Jun 30, 2026: cash $12.2M, total assets $13.5M, total liabilities $1.78M, shareholders' equity $11.8M
- Mar 31, 2026: cash $5.86M, total assets $7.12M, total liabilities $3.25M, shareholders' equity $3.87M
- Dec 31, 2025: cash $1.00M, total assets $1.31M, total liabilities $7.69M, shareholders' equity −$6.38M
- Sep 30, 2025: cash n/a, total assets $2.40M, total liabilities $13.9M, shareholders' equity −$11.5M
- Jun 30, 2025: cash n/a, total assets $989K, total liabilities $10.6M, shareholders' equity −$9.62M
- Mar 31, 2025: cash n/a, total assets $1.97M, total liabilities $9.92M, shareholders' equity −$7.95M
- Dec 31, 2024: cash n/a, total assets $148K, total liabilities $1.69M, shareholders' equity −$1.54M
- Sep 30, 2024: cash n/a, total assets $6.66M, total liabilities $6.57M, shareholders' equity −$774K
What is ASBP's revenue?
ASPIRE BIOPHARMA HLDGS INC reported $6.20K of revenue for the fiscal year ended December 2025.
Is ASBP profitable?
No. ASPIRE BIOPHARMA HLDGS INC lost $11.0M over the last four quarters.
What is ASBP's EPS?
Diluted earnings per share over the last four quarters were $514.90; −$1.22 in the latest quarter.